Antimicrobial resistance: Emerging challenges, prevention approaches, and the critical need for new drug development

Objective Antimicrobial resistance (AMR) is a major global health challenge that compromises the effectiveness of antimicrobial therapy and accelerates the emergence of multidrug-resistant bacterial infections. This review critically integrates current evidence on bacterial AMR mechanisms, global epidemiology, and emerging therapeutic strategies while evaluating their clinical applicability, evidence strength, and translational limitations. Methods A critical narrative review was conducted using peer-reviewed articles, clinical studies, systematic reviews, surveillance reports, and guidance documents retrieved from PubMed, Scopus, Web of Science, and Google Scholar. The primary literature search covered publications from 2005 to 2025, while landmark studies published before 2005 were included to provide historical context. Literature was selected based on scientific quality, relevance to bacterial AMR, and translational significance. Results Bacterial AMR is driven by multiple mechanisms, including enzymatic drug inactivation, target modification, efflux pump overexpression, reduced membrane permeability, biofilm formation, and horizontal gene transfer. Emerging therapeutic approaches, including artificial intelligence-assisted drug discovery, CRISPR-Cas systems, antimicrobial peptides, antibody–antibiotic conjugates, and nanotechnology-based delivery platforms, demonstrate considerable potential for overcoming resistance. However, their clinical translation remains limited by insufficient clinical validation, delivery challenges, toxicity concerns, scalability, reproducibility, and regulatory uncertainty. Conclusion Addressing AMR requires integrated multidisciplinary strategies that combine mechanistic understanding, epidemiological surveillance, antimicrobial stewardship, and translational therapeutic development. Future progress will depend on rigorous clinical validation, scalable implementation, and coordinated global efforts to optimize antimicrobial management and accelerate therapeutic innovation.